Submitted by Armen Hareyan on Feb 4th, 2008
Facial Rejuvenation
Obagi Medical announced the results of a wide-ranging investigator assessment study on the effects of its Condition & Enhance System on facial rejuvenation procedures. The data show that the unique 4% hydroquinone- based system in combination with common non-surgical and surgical facial rejuvenation procedures improved overall skin quality in up to 80 percent of subjects.
As rated by investigators, eighty-three percent of patients treated with the Condition & Enhance System and botulinum toxin type A injections (i.e., Botox) experienced a 1-grade improvement (from moderate to mild or mild to none) in hyperpigmentation. Additionally, 33 percent of subjects achieved a 2-grade improvement (from severe to mild or moderate to none) in this type of sun damage related discoloration. Similar levels of improvement were also seen in tactile roughness and sallowness. These results are independent of the effects of botulinum toxin type A, therefore supporting the benefit of using the unique Condition & Enhance System in order to provide a more balanced overall aesthetic result.
The 4% hydroquinone-based skin care program, known commercially as the Obagi Condition & Enhance System, helps correct premature photoaged skin and prevent future skin damage. The system is comprised of products that work together to improve overall skin health and appearance. The Condition & Enhance System, utilizing Obagi's Penetrating Therapeutics, includes cleanser, toner, 4% hydroquinone, exfoliant, and sunscreen SPF 35 for complete skin care.
"Using the Condition & Enhance System, with 4% hydroquinone, improves overall skin quality and is an effective adjunct to both non-surgical and surgical facial rejuvenation procedures," said Jody Comstock, MD, Skin Spectrum, Tucson, AZ, and lead investigator. "With continued advances in technology, the number of cosmetic dermatology procedures is on the rise and it is important to have a safe, effective skin care regimen to complement these procedures and address total skin rejuvenation and the maintenance of skin improvement."
Other results of the study include:
-- Investigators gave ratings of "good" or "excellent" improvement in overall skin quality in at least 80 percent of patients treated with the Obagi Condition & Enhance System as pre and post-conditioning in combination with:
-- Botulinum toxin type A
-- Intense pulsed light therapy
-- Non-ablative laser therapy
-- Ablative chemical peel
-- Surgery
-- Investigators gave ratings of "good" or "excellent" improvement in overall skin quality in at least 70% of patients treated with the Obagi Condition & Enhance System as pre and post-conditioning in combination with:
-- Non-ablative chemical peel
-- Microdermabrasion
-- Ablative laser therapy
-- Laser resurfacing
Of the more than 2,500 patients assessed in the study, 52 percent had non- ablative/non-surgical procedures such as botulinum toxin type A injections, intense pulsed light therapy, and filler injections, while 46 percent had ablative/surgical procedures such as laser therapy, chemical peels, and surgery. Patients used the Condition & Enhance System in conjunction with their facial rejuvenation procedure to enhance their overall aesthetic result. Mean duration of use of the Condition & Enhance System in this study was 4 weeks pre-conditioning and 6 weeks post-conditioning.
The order and frequency of application of Condition & Enhance are carefully defined and managed by the physician to create a 4-step process for improving and restoring overall skin quality. The first step is skin preparation, the second step is skin correction, the third step is skin stimulation, and the fourth step is skin protection.
"The results of this large-scale study reinforce the efficacy and tolerability of Condition & Enhance, and we are pleased to provide a system that works in concert with some of today's most sought-after facial rejuvenation procedures to help improve clinical outcomes," said Steve Carlson, President & CEO, Obagi Medical Products, Inc.
Source:
Obagi Medical Products, Inc. 